UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

NOTICE OF EFFECTIVENESS

Effective Date:June 07,
XTL Biopharmaceuticals (NASDAQ:XTLB)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025 Click aqui para mais gráficos XTL Biopharmaceuticals.
XTL Biopharmaceuticals (NASDAQ:XTLB)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025 Click aqui para mais gráficos XTL Biopharmaceuticals.

Notícias Xtl Biopharmaceuticals Ltd

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Segunda, 30 de Dezembro de 2024 (4 dias atrás) • Edgar (US Regulatory)
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Segunda, 30 de Dezembro de 2024 (4 dias atrás) • Edgar (US Regulatory)
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Terça, 19 de Novembro de 2024 (1 mês atrás) • Edgar (US Regulatory)
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Terça, 12 de Novembro de 2024 (2 meses atrás) • Edgar (US Regulatory)
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Terça, 15 de Outubro de 2024 (3 meses atrás) • Edgar (US Regulatory)
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Quarta, 14 de Agosto de 2024 (5 meses atrás) • Edgar (US Regulatory)
XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million
Quarta, 14 de Agosto de 2024 (5 meses atrás) • GlobeNewswire Inc.
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Segunda, 22 de Julho de 2024 (5 meses atrás) • Edgar (US Regulatory)
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Quarta, 12 de Junho de 2024 (7 meses atrás) • Edgar (US Regulatory)
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Quarta, 5 de Junho de 2024 (7 meses atrás) • Edgar (US Regulatory)
XTL Entered Definitive Agreement to Acquire The Social Proxy
Quarta, 5 de Junho de 2024 (7 meses atrás) • GlobeNewswire Inc.
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Segunda, 13 de Maio de 2024 (8 meses atrás) • Edgar (US Regulatory)

Mais Notícias de Xtl Biopharmaceuticals Ltd